CTOs on the Move

Accreditation Council for Graduate Medical Educa

www.acgme.org

 
The Accreditation Council for Graduate Medical Education (ACGME) is a private, non-profit, professional organization responsible for the accreditation of approximately 10,000 residency and fellowship programs and the approximately 800 institutions that sponsor these programs in the United States. Residency and fellowship programs educate approximately 125,000 resident and fellow physicians in 150 specialties and subspecialties. The ACGME`s mission is to improve health care and population health by assessing and advancing the quality of resident physicians` education through accreditation. We imagine a world characterized by: • A structured approach to evaluating the competency of all residents and fellows, • Motivated physician role ...
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.acgme.org
  • 401 North Michigan Avenue Suite 2000
    Chicago, IL USA 60611
  • Phone: 312.755.5000

Executives

Name Title Contact Details

Similar Companies

Echo Solution

Echo, a HealthStream Company, is a combination of two industry leading software development companies, HealthLine Systems and Sy.Med Development. Echo develops and supports a comprehensive solution set for healthcare provider credentialing, privileging, enrollment, referral, onboarding, and analytics. Echo is supported by an industry leading development and client services staff with significant combined experience in the healthcare industry.

Preferred Commerce

Preferred Commerce, Inc. (OCBM) is the supplier and provider of Elev8, products that contain some of the world`s most powerful antioxidants and cell reparation enzymes such as SOD (Superoxide Dismutase) mononucleotides and other key ingredients that promote healthier cell activity in all living things. SOD is an enzyme that alternately catalyzes the dismutation (or partitioning) of the superoxide (O2-) radical into either ordinary molecular oxygen (O2) or hydrogen peroxide (H2O2). Hydrogen peroxide is also damaging and is degraded by other enzymes such as catalase. Preferred Commerce`s specially formulated Elev8 products have been shown to provide relief to people who have Rheumatoid Arthritis, visible signs of skin damage, Scleroderma, Cataracts, Gout, inflammation, Interstitial Cystitis, Osteoarthritis, Parkinson`s Disease, Alzheimer`s disease, and ADHD, not to mention providing a stimulus for overall healthier lifestyles, cardiovascular health, and mental capacity and focus to people without any known health issues. Preferred Commerce has long been a solution provider to the horticulture and agriculture industries, as well as to consumers. In addition, the company has created training and educational products that have fueled billions of dollars in sales for Fortune 500 companies, while its family-friendly how-to-grow products have educated nearly 1 million children on how to successfully grow their own healthy food at home. As today`s health concerns are escalating, Preferred Commerce feels that Elev8 can play an important part in providing people with healthier lifestyles.

MP Biomedicals

MP Biomedicals is a Solon, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TriHealth

TriHealth is the healthcare system that formed as a partnership between Good Samaritan Hospital and Bethesda Hospital, Inc. Through acute care hospitals and more than 80 locations, TriHealth provides a wide range of clinical, educational, preventive an...

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.